Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 31 to 40 of 628 total matches.

Cabtreo: A Three-Drug Gel for Acne

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024  (Issue 1700)
) significantly more than its vehicle alone (see Table 1). In a phase 2, randomized, double-blind trial, 741 ...
The FDA has approved Cabtreo (Bausch Health), a gel containing the retinoid adapalene, the oxidizing agent benzoyl peroxide, and the antibiotic clindamycin, for treatment of acne vulgaris in patients ≥12 years old. Cabtreo is the first three-drug topical formulation to become available in the US for treatment of acne.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):59-60   doi:10.58347/tml.2024.1700b |  Show IntroductionHide Introduction

Semaglutide (Wegovy) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
of obesityrelated comorbidities.4 MECHANISM OF ACTION — Activation of brain GLP-1 receptors potentiates glucose ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has now been approved in a higher dose as Wegovy (Novo Nordisk) for chronic weight management in adults with or without type 2 diabetes who have a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia). An oral formulation of semaglutide...
Med Lett Drugs Ther. 2021 Jul 12;63(1628):106-8 |  Show IntroductionHide Introduction

A Renal Indication for Semaglutide (Ozempic)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk) has been approved ...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk) has been approved by the FDA to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). It is the first GLP-1 receptor agonist to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):38-40   doi:10.58347/tml.2025.1723d |  Show IntroductionHide Introduction

Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
trials included applicationsite pain (10.6%), dryness (4.9%), exfoliation (4.1%), erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream containing the retinoid tretinoin and the oxidizing agent benzoyl peroxide, for once-daily topical treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2022 May 16;64(1650):75-6 |  Show IntroductionHide Introduction

Minocycline Foam (Zilxi) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
Minocycline Foam (Zilxi) for Rosacea The FDA has approved a 1.5% topical foam formulation ...
The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi – Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer markets minocycline foam 4% (Amzeeq) for treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):179-80 |  Show IntroductionHide Introduction

Semaglutide (Ozempic) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo ...
In recently published clinical trials, once-weekly subcutaneous injection of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has reduced body weight significantly in patients with and without type 2 diabetes when given in addition to lifestyle intervention. Liraglutide (Saxenda), another GLP-1 receptor agonist, has been FDA-approved for chronic weight...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):53-4 |  Show IntroductionHide Introduction

In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
(CKD).1,2 FINERENONE — Finerenone was approved by the FDA in 2021 to reduce the risk of sustained ...
Recently published guidelines from the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group recommend addition of the oral nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to standard treatment in patients with type 2 diabetes and chronic kidney disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6   doi:10.58347/tml.2023.1668e |  Show IntroductionHide Introduction

Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2025  (Issue 1735)
Volume 67 Published online July 22, 2025 Lenacapavir (Yeztugo) for HIV-1 Pre-Exposure Prophylaxis ...
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Yeztugo – Gilead) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adolescents and adults. Lenacapavir is the first drug to be approved for this indication that is given twice-yearly; other drugs approved for this indication are given once daily or once every 2 months. Lenacapavir was approved in 2022 as Sunlenca for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced...
Med Lett Drugs Ther. 2025 Aug 18;67(1735):132-4   doi:10.58347/tml.2025.1735c |  Show IntroductionHide Introduction

An EUA for Bamlanivimab and Etesevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
(see Table 1).1 Bamlanivimab received an EUA for use as monotherapy in such patients in November ...
The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease and/or hospitalization (see Table 1). Bamlanivimab received an EUA for use as monotherapy in such patients in November 2020. Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) are also authorized for use...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50 |  Show IntroductionHide Introduction

In Brief: Alternatives to Bicillin L-A

   
The Medical Letter on Drugs and Therapeutics • Aug 28, 2025  (Issue 5119)
identified during visual inspection.1 The CDC has issued a "Dear Colleague Letter" to alert healthcare ...
On July 10, 2025 Pfizer issued a voluntary recall of certain lots of long-acting intramuscular (IM) benzathine penicillin G (Bicillin L-A) due to particulates identified during visual inspection. The CDC has issued a "Dear Colleague Letter" to alert healthcare providers about the recall and provide advice on how to manage the potentially limited supply of the drug for treatment of syphilis, which has been increasing in the US.2 Benzathine penicillin G is also used for treatment of group A streptococcal pharyngitis and prophylaxis of rheumatic fever.
Med Lett Drugs Ther. 2025 Aug 28;67(5119):1-2   doi:10.58347/tml.2025.5119a |  Show IntroductionHide Introduction